tbuckley/cabot-search huggingface dataset:
Disruption of actin dynamics regulated by Rho effector mDia1 attenuates pressure overload-induced cardiac hypertrophic responses and exacerbates dysfunction
Authors: Ichitaro Abe, Takeshi Terabayashi, Katsuhiro Hanada, Hidekazu Kondo, Yasushi Teshima, Yumi Ishii, Miho Miyoshi, Shintaro Kira, Shotaro Saito, Hirotsugu Tsuchimochi, Mikiyasu Shirai, Kunio Yufu, Motoki Arakane, Tsutomu Daa, Dean Thumkeo, Shuh Narumiya, Naohiko Takahashi, Toshimasa Ishizaki
Journal: Cardiovascular Research (2020)

Abstract Aims Cardiac hypertrophy is a compensatory response to pressure overload, leading to heart failure. Recent studies have demonstrated that Rho is immediately activated in left ventricles after pressure overload and that Rho signalling plays crucial regulatory roles in actin cytoskeleton rearrangement during cardiac hypertrophic responses. However, the mechanisms by which Rho and its downstream proteins control actin dynamics during hypertrophic responses remain not fully understood. In this study, we identified the pivotal roles of mammalian homologue of Drosophila diaphanous (mDia) 1, a Rho-effector molecule, in pressure overload-induced ventricular hypertrophy. Methods and results Male wild-type (WT) and mDia1-knockout (mDia1KO) mice (10–12 weeks old) were subjected to a transverse aortic constriction (TAC) or sham operation. The heart weight/tibia length ratio, cardiomyocyte cross-sectional area, left ventricular wall thickness, and expression of hypertrophy-specific genes were significantly decreased in mDia1KO mice 3 weeks after TAC, and the mortality rate was higher at 12 weeks. Echocardiography indicated that mDia1 deletion increased the severity of heart failure 8 weeks after TAC. Importantly, we could not observe apparent defects in cardiac hypertrophic responses in mDia3-knockout mice. Microarray analysis revealed that mDia1 was involved in the induction of hypertrophy-related genes, including immediate early genes, in pressure overloaded hearts. Loss of mDia1 attenuated activation of the mechanotransduction pathway in TAC-operated mice hearts. We also found that mDia1 was involved in stretch-induced activation of the mechanotransduction pathway and gene expression of c-fos in neonatal rat ventricular cardiomyocytes (NRVMs). mDia1 regulated the filamentous/globular (F/G)-actin ratio in response to pressure overload in mice. Additionally, increases in nuclear myocardin-related transcription factors and serum response factor were perturbed in response to pressure overload in mDia1KO mice and to mechanical stretch in mDia1 depleted NRVMs. Conclusion mDia1, through actin dynamics, is involved in compensatory cardiac hypertrophy in response to pressure overload.
Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan
Authors: Scott D. Solomon, Pardeep S. Jhund, Brian L. Claggett, Pooja Dewan, Lars Køber, Mikhail N. Kosiborod, Felipe A. Martinez, Piotr Ponikowski, Marc S. Sabatine, Silvio E. Inzucchi, Akshay S. Desai, Olof Bengtsson, Daniel Lindholm, Mikaela Sjostrand, Anna Maria Langkilde, John J.V. McMurray
Journal: JACC Heart Failure (2020)
P-178 Prognostic impact of immune-related adverse events with nivolumab or pembrolizumab monotherapy in patients with advanced gastric cancer: A multicenter retrospective analysis
Authors: I. Motoo, T. Ando, A. Ueda, K. Ogawa, S. Kajiura, K. Hirano, T. Okumura, K. Tsukada, T. Hara, N. Suzuki, N. Nakada, S. Takatori, N. Horikawa, T. Fujii, I. Yasuda
Journal: Annals of Oncology (2020)
Influence of Distance and Near Visual Impairment on Self-Reported Near Visual Functioning in a Multinational Study
Authors: Xiaotong Han, Leon B. Ellwein, Amza Abdou, Kovin S. Naidoo, Yuddha D. Sapkota, R.D. Thulasiraj, Rohit Varma, Jialiang Zhao, Mingguang He
Journal: Ophthalmology (2020)
P-294 Incorporating genetic counseling service into the gastrointestinal tumor board: Experience, obstacles, and opportunities in a Mexican center
Authors: G. Pacheco-Cuellar, I. Castañeda-Saldaña, J. Valdez-Andrade, M. Gonzalez-Guadarrama, I. Padilla-Mota, M. Rodriguez-Campa, A. Blanco-Salazar, J. Barrera-Franco, S. Campos-Gomez
Journal: Annals of Oncology (2020)
Abstract 11199: Downregulation of SR Ca2+-ATPase in Monkeys With Chronic Heavy Alcohol Consumption: A Key Molecular Mechanism of Alcoholic Cardiomyopathy
Authors: Che Ping Cheng, Nadeen Wajih, Heng-Jie Cheng, Qun Shao, David Friedman, James B Daunais, Kathleen A Grant
Journal: Circulation (2018)

Background: Recent evidence indicates that the main effect of chronic alcohol ingestion is the loss of left ventricle (LV) contractility that progressively induces the development of alcoholic card...
P-55 GASTHER2: Efficacy of adding trastuzumab to standard chemotherapy in patients with advanced HER2-negative gastric cancer and HER2-positive expression in circulating tumor cells
Authors: R. Riechelmann, M. Donadio, V. Jesus, T. Felismino, C. Mello, V. Souza e Silva, M. Barros e Silva, M. Camandaroba, N. Rodrigues, A. Dettino, L. Chinen
Journal: Annals of Oncology (2020)
Core and adjunctive interventions for osteoarthritis: efficacy and models for implementation
Authors: Jocelyn L. Bowden, David J. Hunter, Leticia A. Deveza, Vicky Duong, Krysia S. Dziedzic, Kelli D. Allen, Ping-Keung Chan, Jillian P. Eyles
Journal: Nature Reviews Rheumatology (2020)
RNA-binding proteins in tumor progression
Authors: Hai Qin, Haiwei Ni, Yichen Liu, Yaqin Yuan, Tao Xi, Xiaoman Li, Lufeng Zheng
Journal: Journal of Hematology & Oncology (2020)

Abstract RNA-binding protein (RBP) has a highly dynamic spatiotemporal regulation process and important biological functions. They are critical to maintain the transcriptome through post-transcriptionally controlling the processing and transportation of RNA, including regulating RNA splicing, polyadenylation, mRNA stability, mRNA localization, and translation. Alteration of each process will affect the RNA life cycle, produce abnormal protein phenotypes, and thus lead to the occurrence and development of tumors. Here, we summarize RBPs involved in tumor progression and the underlying molecular mechanisms whereby they are regulated and exert their effects. This analysis is an important step towards the comprehensive characterization of post-transcriptional gene regulation involved in tumor progression.
P-159 First-in-human phase 1 dose-escalating study protocol of pressurized intraperitoneal aerosol chemotherapy with paclitaxel in peritoneal carcinomatosis (PIPAC2 study)
Authors: G. Kim, H. Tan, R. Sundar, L. Wang, A. Shabbir, W. Yong, J. So
Journal: Annals of Oncology (2020)
Very Early Recurrence After Liver Resection for Intrahepatic Cholangiocarcinoma
Authors: Diamantis I. Tsilimigras, Kota Sahara, Lu Wu, Dimitrios Moris, Fabio Bagante, Alfredo Guglielmi, Luca Aldrighetti, Matthew Weiss, Todd W. Bauer, Sorin Alexandrescu, George A. Poultsides, Shishir K. Maithel, Hugo P. Marques, Guillaume Martel, Carlo Pulitano, Feng Shen, Olivier Soubrane, B. Groot Koerkamp, Amika Moro, Kazunari Sasaki, Federico Aucejo, Xu-Feng Zhang, Ryusei Matsuyama, Itaru Endo, Timothy M. Pawlik
Journal: JAMA Surgery (2020)

Although surgery offers the best chance of a potential cure for patients with localized, resectable intrahepatic cholangiocarcinoma (ICC), prognosis of patients remains dismal largely because of a high incidence of recurrence.To predict very early recurrence (VER) (ie, recurrence within 6 months after surgery) following resection for ICC in the pre- and postoperative setting.Patients who underwent curative-intent resection for ICC between May 1990 and July 2016 were identified from an international multi-institutional database. The study was conducted at The Ohio State University in collaboration with all other participating institutions. The data were analyzed in December 2019.Two logistic regression models were constructed to predict VER based on pre- and postoperative variables. The final models were used to develop an online calculator to predict VER and the tool was internally and externally validated.Among 880 patients (median age, 59 years [interquartile range, 51-68 years]; 388 women [44.1%]; 428 [50.2%] white; 377 [44.3%] Asian; 27 [3.2%] black]), 196 (22.3%) developed VER. The 5-year overall survival among patients with and without VER was 8.9% vs 49.8%, respectively (P < .001). A preoperative model was able to stratify patients relative to the risk for VER: low risk (6-month recurrence-free survival [RFS], 87.7%), intermediate risk (6-month RFS, 72.3%), and high risk (6-month RFS, 49.5%) (log-rank P < .001). The postoperative model similarly identified discrete cohorts of patients based on probability for VER: low risk (6-month RFS, 90.0%), intermediate risk (6-month RFS, 73.1%), and high risk (6-month RFS, 48.5%) (log-rank, P < .001). The calibration and predictive accuracy of the pre- and postoperative models were good in the training (C index: preoperative, 0.710; postoperative, 0.722) as well as the internal (C index: preoperative, 0.715; postoperative, 0.728; bootstrapping resamples, n = 5000) and external (C index: postoperative, 0.672) validation data sets.An easy-to-use online calculator was developed to help clinicians predict the chance of VER after curative-intent resection for ICC. The tool performed well on internal and external validation. This tool may help clinicians in the preoperative selection of patients for neoadjuvant therapy as well as during the postoperative period to inform surveillance strategies.
Corrigendum to ‘Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study’
Authors: F. Pagès, T. André, J. Taieb, D. Vernerey, J. Henriques, C. Borg, F. Marliot, R. Ben Jannet, C. Louvet, L. Mineur, J. Bennouna, J. Desrame, R. Faroux, A. Kirilovsky, A. Duval, P. Laurent-Puig, M. Svrcek, F. Hermitte, A. Catteau, J. Galon, J-F. Emile
Journal: Annals of Oncology (2020)

The authors regret that in the original publication the affiliations of Dr Svrcek were incorrectly given. The correct affiliations are as above. The authors would like to apologise for any inconvenience caused. Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort studyAnnals of OncologyVol. 31Issue 7PreviewThe Immunoscore (IS), which prognostically classifies stage I–III colon cancer (CC) patients, was evaluated in the International Duration Evaluation of Adjuvant Therapy (IDEA) France cohort study investigating 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy in stage III CC patients. Full-Text PDF Open Archive
Abstract 13823: Development of a Community-Engagement Regional Equity Consortium to Address Cardiovascular Disease Disparities in Diverse Communities: The Northeast Health Equity Consortium (NHEC)
Authors: Lenny Lopez, Benjamin Perkins, Marcus M McKinney, Sean Cahill
Journal: Circulation (2019)

Introduction: Aligning with the strategic missions of the NHLBI and other governmental agencies, the AHA Founders Affiliate established the Northeast Health Equity Consortium (NHEC) in 2016 focused...
P-219 Clear cell variant of hepatocellular carcinoma (HCC-CC): A single-center observational study of an uncommon subtype
Authors: F. Salani, I. Pecora, C. Vivaldi, V. Massa, S. Catanese, L. Bernardini, M. Caccese, S. Cesario, E. Vasile, M. Lencioni, L. Fornaro, A. Falcone, G. Masi
Journal: Annals of Oncology (2020)
P-243 Incidence and survival of pancreatic neuroendocrine tumours in Girona, Spain
Authors: R. Fort Culillas, C. Carmona Garcia, G. Osca Geli, R. Marcos-Gragera, M. Puigdemont Guinart, J. Biarnes Costa, S. Lopez-Ben, A. García Velasco, R. Guardeño Sanchez
Journal: Annals of Oncology (2020)
P-143 Lack of expression of CDX2: Prognostic biomarker in stage IV colorectal cancer
Authors: A. Soares, D. Rodrigues, E. Cipriano, A. Tavares, M. Vilaca, D. Silva, J. Santos, A. Mesquita, M. Salgado, C. Sottomayor, R. Almeida
Journal: Annals of Oncology (2020)
P-162 Perioperative capecitabine-oxaliplatin chemotherapy in resectable gastric cancer
Authors: A. Arab, S. Belhadef, B. Benamor, I. Mesrour, K. Mechta, H. Megari, D. Hammouda, M. Kheloufi, M. Rebaine, H. Mahfouf
Journal: Annals of Oncology (2020)
P-192 ART SCORE in determining the feasibility of TACE in hepatocarcinoma
Authors: F. Macedo, T. Cunha Pereira, R. Félix Soares, A. Monteiro, N. Bonito, J. Ribeiro, J. Paulo, P. Jacinto, M. Marques, G. Sousa
Journal: Annals of Oncology (2020)
Association of Factor V Leiden With Subsequent Atherothrombotic Events
Authors: Bakhtawar K. Mahmoodi, Vinicius Tragante, Marcus E. Kleber, Michael V. Holmes, Amand F. Schmidt, Raymond O. McCubrey, Laurence J. Howe, Kenan Direk, Hooman Allayee, Ekaterina V. Baranova, Peter S. Braund, Graciela E. Delgado, Niclas Eriksson, Crystel M. Gijsberts, Yan Gong, Jaana Hartiala, Mahyar Heydarpour, Gerard Pasterkamp, Salma Kotti, Pekka Kuukasjärvi, Petra A. Lenzini, Daniel Levin, Leo-Pekka Lyytikäinen, Jochen D. Muehlschlegel, Christopher P. Nelson, Kjell Nikus, Anna P. Pilbrow, W.H. Wilson Tang, Sander W. van der Laan, Jessica van Setten, Ragnar O. Vilmundarson, John Deanfield, Panos Deloukas, Frank Dudbridge, Stefan James, Ify R Mordi, Andrej Teren, Thomas O. Bergmeijer, Simon C. Body, Michiel Bots, Ralph Burkhardt, Rhonda M. Cooper-DeHoff, Sharon Cresci, Nicolas Danchin, Robert N. Doughty, Diederick E. Grobbee, Emil Hagström, Stanley L. Hazen, Claes Held, Imo E. Hoefer, G. Kees Hovingh, Julie A. Johnson, Marcin P. Kaczor, Mika Kähönen, Olaf H. Klungel, Jari O. Laurikka, Terho Lehtimäki, Anke H. Maitland-van der Zee, Ruth McPherson, Colin N. Palmer, Adriaan O. Kraaijeveld, Carl J. Pepine, Marek Sanak, Naveed Sattar, Markus Scholz, Tabassome Simon, John A. Spertus, Alexandre F.R. Stewart, Wojciech Szczeklik, Joachim Thiery, Frank L.J. Visseren, Johannes Waltenberger, A. Mark Richards, Chim C. Lang, Vicky A. Cameron, Axel Åkerblom, Guillaume Pare, Winfried März, Nilesh J. Samani, Aroon D. Hingorani, Jurriën M. ten Berg, Lars Wallentin, Folkert W. Asselbergs, Riyaz S. Patel
Journal: Circulation (2020)

Studies examining the role of factor V Leiden among patients at higher risk of atherothrombotic events, such as those with established coronary heart disease (CHD), are lacking. Given that coagulation is involved in the thrombus formation stage on atherosclerotic plaque rupture, we hypothesized that factor V Leiden may be a stronger risk factor for atherothrombotic events in patients with established CHD.
SO-18 Single-arm multicentre phase II study of bevacizumab (B) combined with 9-weekly alternating CAPOX and CAPIRI as first-line treatment of patients with metastatic colorectal cancer (mCRC): Main results of the AXOAXI-trial
Authors: P. Osterlund, P. Halonen, T. Salminen, L. Soveri, E. Osterlund, P. Nyandoto, V. Salminen, N. Paunu, K. Lehtomäki, R. Huuhtanen, T. Luukkaala, P. Kellokumpu-Lehtinen, P. Bono, H. Isoniemi
Journal: Annals of Oncology (2020)
Abstract 16295: Endothelial Discoidin Domain Receptor 2 Promote Angiogenesis Through JAK-STAT3 Signaling Pathway
Authors: Shuya Zhang, Ting-ting Wang, Huan Liu, Zheng-Gen Jin, XiuYing Pei
Journal: Circulation (2018)

Periodic ovarian angiogenesis is crucial for follicular maturation and corpus luteum formation. Several prominent studies have indicated that extracellular matrix (ECM) in ovary microenvironment pl...
SO-11 Molecular evaluation of Helicobacter pylori infection in 470 Colombian patients with premalignant lesion and gastric cancer
Authors: A. Guevara-Tique, J. Suarez Olaya, F. Castro-Valencia, G. Parra Gil, R. Torres, J. Torres, L. Carvajal Carmona, M. Echeverry de Polanco, M. Bohorquez Lozano
Journal: Annals of Oncology (2020)
Characteristics of the Multiplicity of Randomized Clinical Trials for Coronavirus Disease 2019 Launched During the Pandemic
Authors: Ramez Kouzy, Joseph Abi Jaoude, Carolina J. Garcia Garcia, Molly B. El Alam, Cullen M. Taniguchi, Ethan B. Ludmir
Journal: JAMA Network Open (2020)

This systematic review examines current randomized clinical trials of therapeutic agents to treat coronavirus disease 2019 (COVID-19).
P-175 Total neoadjuvant treatment versus standard therapy (neoadjuvant radiochemotherapy and adjuvant chemotherapy) of rectal cancer with high-risk factors for local or systemic recurrence
Authors: M. Tuta, N. Boc, M. Peternel, F. Anderluh, I. Oblak, A. Secerov-Ermenc, A. Jeromen Peressutti, E. Brecelj, V. Velenik
Journal: Annals of Oncology (2020)
P-147 Efficacy and safety data of trifluridine/tipiracil treatment in advanced colorectal cancer based on the experience of Juan Ramón Jiménez Hospital in Huelva
Authors: M. Amor Urbano, V. Aviñó Tarazona, M. Amérigo Góngora, M. Bolaños Naranjo, J. Bayo Calero
Journal: Annals of Oncology (2020)
Finding the Brain in the Nose
Authors: David H. Brann, Sandeep Robert Datta
Journal: Annual Review of Neuroscience (2020)

Olfaction is fundamentally distinct from other sensory modalities. Natural odor stimuli are complex mixtures of volatile chemicals that interact in the nose with a receptor array that, in rodents, is built from more than 1,000 unique receptors. These interactions dictate a peripheral olfactory code, which in the brain is transformed and reformatted as it is broadcast across a set of highly interconnected olfactory regions. Here we discuss the problems of characterizing peripheral population codes for olfactory stimuli, of inferring the specific functions of different higher olfactory areas given their extensive recurrence, and of ultimately understanding how odor representations are linked to perception and action. We argue that, despite the differences between olfaction and other sensory modalities, addressing these specific questions will reveal general principles underlying brain function.
Reward Contributions to Serotonergic Functions
Authors: Zhixiang Liu, Rui Lin, Minmin Luo
Journal: Annual Review of Neuroscience (2020)

The brain serotonin systems participate in numerous aspects of reward processing, although it remains elusive how exactly serotonin signals regulate neural computation and reward-related behavior. The application of optogenetics and imaging techniques during the last decade has provided many insights. Here, we review recent progress on the organization and physiology of the dorsal raphe serotonin neurons and the relationships between their activity and behavioral functions in the context of reward processing. We also discuss several interesting theories on serotonin's function and how these theories may be reconciled by the possibility that serotonin, acting in synergy with coreleased glutamate, tracks and calculates the so-called beneficialness of the current state to guide an animal's behavior in dynamic environments.
Inhibition of breast cancer metastasis and development using short length heparin oligosaccharides
Authors: Paul Mellor, James Harvey, Simi Ali, John Kirby, T W J Lennard
Journal: Cancer Research (2006)

2402  Metastatic breast cancer cells express high levels of the chemokine receptor CXCR4. Furthermore it has been shown that CXCL12, the sole ligand for CXCR4, is constitutively expressed within many organs associated with breast cancer metastasis. The interaction between CXCR4 on breast cancer cells and CXCL12, presented by heparan sulphate (HS) on the apical surface of the vascular endothelium and in the extracellular matrix, facilitates invasion of the organ by breast cancer cells. The current study was performed to maximise the potential of defined oligosaccharides of heparin to disrupt normal interactions between CXCR4 and CXCL12, whilst minimising the anticoagulant properties of these molecules. Further studies were performed in vivo to assess the potential of an optimised 12-mer heparin oligosaccharide to inhibit the metastatic spread and growth of breast cancer. Radioligand competition binding assays were performed using a range of heparin-derived sulphated oligosaccharides (8-26 mer) to compete against HS for binding of I125 CXCL12. A dp12 (degrees of polymerization; 12 monosaccharide units) oligosaccharide was the smallest derivative of heparin to compete efficiently (71% inhibition; p
Desenvolvimento de uma rede europeia para diagnóstico de doenças virais "importadas" (ENIVD)
Authors: M Niedrig, B Niklasson, G Lloyd, H Schmitz, B LeGuenno
Journal: Eurosurveillance (1998)

As recentes epidemias de febre hemorragica por virus Ebola, no Zaire e no Gabao, fizeram lembrar que infeccoes perigosas podem ser importadas para a Europa, muito rapidamente. As reunioes, organizadas pela Organizacao Mundial de Saude (OMS) em 1993 e 1994 (1,2), sobre patogenios emergentes e re-emergentes, focaram-se nos problemas dos arbovirus e virus das febres hemorragicas e na necessidade de formar uma rede mundial para a troca de informacao, reagentes e metodologias.
Intraspecific Adaptation Load: A Mechanism for Species Coexistence
Authors: Masato Yamamichi, Daisuke Kyogoku, Ryosuke Iritani, Kazuya Kobayashi, Yuma Takahashi, Kaori Tsurui-Sato, Akira Yamawo, Shigeto Dobata, Kazuki Tsuji, Michio Kondoh
Journal: Trends in Ecology & Evolution (2020)
Controversies on the Consequences of Iron Overload and Chelation in MDS
Authors: Francesca Vinchi, Saskia Hell, Uwe Platzbecker
Journal: HemaSphere (2020)

Abstract Many patients with MDS are prone to develop systemic and tissue iron overload in part as a consequence of disease‐immanent ineffective erythropoiesis. However, chronic red blood cell transfusions, which are part of the supportive care regimen to correct anemia, are the major source of iron overload in MDS. Increased systemic iron levels eventually lead to the saturation of the physiological systemic iron carrier transferrin and the occurrence of non‐transferrin‐bound iron (NTBI) together with its reactive fraction, the labile plasma iron (LPI). NTBI/LPI‐mediated toxicity and tissue iron overload may exert multiple detrimental effects that contribute to the pathogenesis, complications and eventually evolution of MDS. Until recently, the evidence supporting the use of iron chelation in MDS was based on anecdotal reports, uncontrolled clinical trials or prospective registries. Despite not fully conclusive, these and more recent studies, including the TELESTO trial, unravel an overall adverse action of iron overload and therapeutic benefit of chelation, ranging from improved hematological outcome, reduced transfusion dependence and superior survival of iron‐loaded MDS patients. The still limited and somehow controversial experimental and clinical data available from preclinical studies and randomized trials highlight the need for further investigation to fully elucidate the mechanisms underlying the pathological impact of iron overload‐mediated toxicity as well as the effect of classic and novel iron restriction approaches in MDS. This review aims at providing an overview of the current clinical and translational debated landscape about the consequences of iron overload and chelation in the setting of MDS.
Localized delivery of CRISPR/dCas9 via layer-by-layer self-assembling peptide coating on nanofibers for neural tissue engineering
Authors: Kunyu Zhang, Wai Hon Chooi, Shuang Liu, Jiah Shin Chin, Aoife Murray, Dean Nizetic, Du Cheng, Sing Yian Chew
Journal: Biomaterials (2020)
Clinical Benefits, Harms, and Cost-Effectiveness of Breast Cancer Screening for Survivors of Childhood Cancer Treated With Chest Radiation
Authors: Jennifer M. Yeh, Kathryn P. Lowry, Clyde B. Schechter, Lisa R. Diller, Oguzhan Alagoz, Gregory T. Armstrong, John M. Hampton, Wendy Leisenring, Qi Liu, Jeanne S. Mandelblatt, Diana L. Miglioretti, Chaya S. Moskowitz, Kevin C. Oeffinger, Amy Trentham-Dietz, Natasha K. Stout
Journal: Annals of Internal Medicine (2020)

Surveillance with annual mammography and breast magnetic resonance imaging (MRI) is recommended for female survivors of childhood cancer treated with chest radiation, yet benefits, harms, and costs are uncertain.